Human 3 with Brom and Sam

16: Josh Bartch, CEO of Mydecine Innovations Group - Psilocybin for smoking cessation, Psilocybin for MDMA & Natural vs Synthetic Psilocybin & is Mydecine Undervalued?

Listen Later

🍄 Josh Bartch is the CEO of Mydecine Innovations Group, a psychedelics company that is researching naturally sourced psychedelic therapeutics targeting PTSD and smoking cessation.  In this episode of The Integration Conversation, Josh joins us for a full hour and tells us about Mydecine's clinical trials, its research on functional mushrooms, and makes his pitch for why Mydecine is undervalued relative to its peers.    


Questions we answer: 

  • Is Mydecine Undervalued? 
  • What lessons from the cannabis boom can we apply to the shroom boom?  
  • Is natural psilocybin better than synthetic psilocybin?  
  • What is the entourage effect?  


    • 🔥 Invest in Psychedelic Startups with Us 🔥 

    go to https://theintegration.co and click on "invest in psychedelic startups"  


    The Integration Conversation is a podcast that covers the emerging psychedelics industry from a business perspective, and aims to be your number 1 resource for investing in psychedelics,  psychedelic investing and psychedelic business.  


    ⛓ All our links:  

    https://theintegration.co 


    📝 My notes on psychedelic investing:  

    https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf   


    🎧 Listen on Spotify and other podcast platforms:  

    https://anchor.fm/theintegrationco 


    🐦 brom on twitter:  

    https://twitter.com/therealbrom 


    🎇 Clips and other stuff on Instagram:  

    https://instagram.com/theintegrationco  


    ⏰ Timestamps: 

    • 0:00 - intro  
    • 3:15 - Myco Overview 
    • 5:45 - who is Josh Bartch? 
    • 9:00 - Are Psychedelics just Cannabis 2.0?  
    • 11:30 - lessons learned in cannabis?  
    • 15:30 - Mydecine Functional Mushroom Research  
    • 21:30 - Mydecine's Psilocybin for PTSD vs MAPS MDMA for PTSD  
    • 27:15 - Natural Psilocybin vs Synthetic Psilocybin  
    • 32:45 - Psilocybin for Smoking Cessation 
    • 48:00 - What does Big Pharma think of psychedelic medicine?  
    • 50:30 - Mydecine clinics?  
    • 53:30 - Is Mydecine Undervalued?  
    • 57:30 - Mydecine NASDAQ uplisting  
    • 1:03:00 - Post Interview Analysis   


      • Disclaimer: This video is not financial advice. Brom holds shares in Mydecine and other psychedelic stocks.

      ...more
      View all episodesView all episodes
      Download on the App Store
      Human 3 with Brom and SamBy Brom Rector and Sam Tabone
      • 5
      • 5
      • 5
      • 5
      • 5

      5

      6 ratings